环境对补偿突变的影响,以改善抗生素耐药性的成本
J Björkman1, I Nagaev, O G Berg
1Department of Bacteriology, Swedish Institute for Infectious Disease Control, S-171 82 Solna, Sweden.
概括
细菌抗生素耐药性往往会产生健康成本,但补偿突变可以演变. 这些突变不同,取决于细菌是在宿主或实验室进化,显示出不同的进化路径.
科学领域:
- 微生物学 微生物学
- 进化生物学 进化生物学
- 遗传学 是一个遗传学.
背景情况:
- 抗生素耐药性是一个主要的公共卫生问题.
- 细菌对抗生素的耐药性往往导致健身成本降低.
- 补偿突变可以演变以减轻这些成本.
研究的目的:
- 研究抗生素耐药性的补偿突变的进化轨迹.
- 为了比较不同环境中的补偿突变的选择 (体内与体外).
主要方法:
- 抗生素耐药细菌的实验进化.
- 在小鼠模型 (in vivo) 中细菌的连续传递.
- 细菌在实验室介质中连续通过 (体外).
主要成果:
- 与实验室介质相比,在小鼠中选择了不同的健身补偿突变组.
- 观察到的差异归因于生长条件特定的突变形成或选择.
- 补偿抗生素耐药性成本的进化途径在宿主环境和实验室环境之间存在显著差异.
结论:
- 细菌进化以克服抗生素耐药性成本取决于环境.
- 与实验室环境相比,宿主环境可以驱动不同的进化轨迹.
- 了解这些差异对于预测和管理抗生素耐药性的演变至关重要.
相关概念视频
Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...


